Publicidad
Contribución especial 26 de mayo de 2024

¿Es el Actinio-225 una oportunidad real para la terapia radionucleídica?

Referenciar Imprimir Descargar PDF

Referencias

  1. Smith RJ, Burpee D. Radionuclide Therapies: An Overview of Applications. Radiol Technol 2021;92:595–614. PMID: 34193577
  2. Stokke C, Kvassheim M, Blakkisrud J. Radionuclides for Targeted Therapy: Physical Properties. Molecules 2022;27:5429. doi: 10.3390/molecules27175429.
  3. Salih S, Alkatheeri A, Alomaim W, Elliyanti A. Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges. Molecules 2022;27:5231. doi: 10.3390/molecules27165231.
  4. Parker C, Lewington V, Shore N, et al. Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review. JAMA Oncol 2018;4:1765–72. doi: 10.1001/jamaoncol.2018.4044.
  5. Guerra Liberal FDC, O'Sullivan JM, McMahon SJ, Prise KM. Targeted Alpha Therapy: Current Clinical Applications. Cancer Biother Radiopharm 2020;35:404–17. doi: 10.1089/cbr.2020.3576.
  6. Nelson BJB, Andersson JD, Wuest F. Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications. Pharmaceutics 2020;13:49. doi: 10.3390/pharmaceutics13010049.
  7. Makvandi M, Dupis E, Engle JW, et al. Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations. Target Oncol 2018;13:189–203. doi: 10.1007/s11523-018-0550-9.
  8. Yang H, Wilson JJ, Orvig C, et al α-Emitting Radionuclides for Therapy: Radiolabeling Method Review. J Nucl Med 2022;63:5–13. doi: 10.2967/jnumed.121.262687.
  9. Engle JW. Production of 225Ac. Curr Radiopharm 2018;11:173–9. doi: 1874-4729/18 $58.00+.00.
  10. Robertson AKH, Ramogida CF, Schaffer P, Radchenko V. Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences. Curr Radiopharm 2018;11:156–72. doi: 10.2174/1874471011666180416161908.
  11. Jiang Z, Revskaya E, Fisher DR, Dadachova E. In vivo Evaluation of Free and Chelated Accelerator-produced 225 Actinium - Radiation Dosimetry and Toxicity Results. Curr Radiopharm 2018;11:215–22. doi: 10.2174/1874471011666180423120707.
  12. Nagatsu K, Suzuki H, Fukada M, et al Cyclotron production of 225Ac from an electroplated 226Ra target. Eur J Nucl Med Mol Imaging 2021;49:279–89. doi: 10.1007/s00259-021-05460-7.
  13. Deblonde GJ-P, Zavarin M, Kersting AB. The coordination properties and ionic radius of actinium: A 120-year-old enigma. Coord Chem Rev 2021;446:214130. doi: 10.1016/j.ccr.2021.214130.
  14. Thiele NA, Wilson JJ. 225 Actinium for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches. Cancer Biother Radiopharm 2018;33:336–48. doi: 10.1089/cbr.2018.2494.
  15. Dhiman D, Vatsa R, Sood A. Challenges and opportunities in developing 225Actinium radiopharmaceuticals. Nucl Med Commun 2022;43:970–7. doi: 10.1016/j.ccr.2021.214130.
  16. Stein B, Kerlin M. Spectroscopic Studies of Highly Radioactive Elements Relevant to Targeted Alpha Therapy. Actinide Research Quarterly, First Quarter 2019. G. T. Seaborg Institute for Transactinium Science Los Alamos National Laboratory, pp. 7–10.
  17. Wilson JJ. Investigating the Chemistry of Actinium, a Therapeutically Relevant Actinide. Actinide Research Quarterly, First Quarter 2019. G. T. Seaborg Institute for Transactinium Science Los Alamos National Laboratory, pp. 4–6.
  18. McDevitt, MR, Ma, D, Simon, J, Frank, RK, Scheinberg, DA. Design and synthesis of 225Ac radioimmunopharmaceuticals. Appl Radiat Isotop 2002;57:841–7. doi: 10.1016/S0969-8043(02)00167-7.
  19. Deal KA, Davis IA, Mirzadeh S, et al. Improved in vivo stability of actinium-225 macrocyclic complexes. J Med Chem 1999;42:2988–92. doi: 10.1021/jm990141f.
  20. Khabibullin AR, Karolak A, Budzevich MM, et al. Structure and properties of DOTA-chelated radiopharmaceuticals within the 225Ac decay pathway. Medchemcomm 2018;9:1155–63. doi: 10.1039/c8md00170g.
  21. Pallares RM, Abergel RJ. Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand? Front Med (Lausanne) 2022;9:1020188. doi: 10.3389/fmed.2022.1020188.
  22. Taylor DM. The metabolism of actinium in the rat. Health Phys 1970;19:411-8. doi: 10.1097/00004032-197009000-00004.
  23. Kozempel J, Mokhodoeva O, Vlk M. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators. Molecules 2018;23:581. doi: 10.3390/molecules23030581.
  24. Lawal IO, Morgenstern A, Vorster M, et al. Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2022;49:3581–92. doi: 10.1007/s00259-022-05778-w.
  25. Feuerecker B, Tauber R, Knorr K, et al. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. Eur Urol 2021;79:343–50. doi: 10.1016/j.eururo.2020.11.013.
  26. Ling SW, de Blois E, Hooijman E, et al. Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer. Pharmaceutics 2022;14:2166. doi: 10.3390/pharmaceutics14102166.
  27. Kleynhans J, Duatti A. The determination of the radiochemical purity of Actinium-225 radiopharmaceuticals: a conundrum. EJNMMI Radiopharm Chem 2022;7:23. doi: 10.1186/s41181-022-00175-y.
  28. Abou DS, Zerkel P, Robben J, et al. Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies. Cancer Biother Radiopharm 2022;37:355–63. doi: 10.1089/cbr.2022.0010.
  29. Kelly JM, Amor-Coarasa A, Sweeney E, et al. A suitable time point for quantifying the radiochemical purity of 225Ac-labeled radiopharmaceuticals. EJNMMI Radiopharm Chem 2021;6:38. doi: 10.1186/s41181-021-00151-y.
  30. Robertson AKH, Ramogida CF, Rodríguez-Rodríguez C, et al. Multi-isotope SPECT imaging of the 225Ac decay chain: feasibility studies. Phys Med Biol 2017;62:4406–20. doi: 10.1088/1361-6560/aa6a99.
  31. Benabdallah N, Scheve W, Dunn N, et al. Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes. Theranostics 2021;11:9721–37. doi: 10.7150/thno.63860.
  32. Koniar H, Rodríguez-Rodríguez C, Radchenko V, et al. SPECT imaging of 226Ac as a theranostic isotope for 225Ac radiopharmaceutical development. Phys Med Biol 2022;67(18). doi: 10.1088/1361-6560/ac8b5f. PMID: 35985341.
  33. [33]Ackerman NL, Graves EE. The potential for Cerenkov luminescence imaging of alpha-emitting radionuclides. Phys Med Biol 2012;57:771–83. doi: 10.1088/0031-9155/57/3/771.
  34. Krasniqi FS, Kerst T, Leino M, et al. Standoff UV-C imaging of alpha particle emitters. Nuclear Inst. and Methods in Physics Research, A, 2021;987:164821. doi: 10.1016/j.nima.2020.164821.
  35. Pandya DN, Hantgan R, Budzevich MM, et al. Preliminary Therapy Evaluation of 225Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from 225Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization. Theranostics 2016;6:698–709. doi: 10.7150/thno.14338.
  36. Seo Y. Quantitative Imaging of Alpha-Emitting Therapeutic Radiopharmaceuticals. Nucl Med Mol Imaging 2019;53:182–8. doi: 10.1007/s13139-019-00589-8.
  37. Vaidyanathan G, Zalutsky MR. Applications of 211At and 223Ra in targeted alpha-particle radiotherapy. Curr Radiopharm 2011;4:283–94. doi: 10.2174/1874471011104040283.
  38. Sindhu KK, Nehlsen AD, Stock RG. Radium-223 for Metastatic Castrate-Resistant Prostate Cancer. Pract Radiat Oncol 2022;12:312–6. doi: 10.1016/j.prro.2022.03.004.
  39. European Medicines Agency (EMA). PRAC assessment report EMA/540557/2018. www.ema.europa.eu/documents/referral/xofigo-article-20-procedure-prac-assessment-report_en.pdf.
  40. INTERNATIONAL ATOMIC ENERGY AGENCY, Guidance for Preclinical Studies with Radiopharmaceuticals, IAEA Radioisotopes and Radiopharmaceuticals Series No. 8, IAEA, Vienna (2023).
  41. Konijnenberg M, Herrmann K, Kobe C, et al. EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. Eur J Nucl Med Mol Imaging 2021;48:67–72. doi.org/10.1007/s00259-020-05038-9.
  42. PRODUCT MONOGRAPH XOFIGO® (radium Ra 223 dichloride solution for injection). 2022, Bayer Inc (http://www.bayer.ca ).
  43. Hoskin P, Sartor O, O'Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15:1397–406. doi: 10.1016/S1470-2045(14)70474-7.
  44. Tronchin S, Forster JC, Hickson K, Bezak E. Dosimetry in targeted alpha therapy. A systematic review: current findings and what is needed. Phys Med Biol 2022;67(9). doi: 10.1088/1361-6560/ac5fe0.